- Home
- MGNX vs CEP Comparison
MGNX vs CEP Comparison
Compare MGNX & CEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- CEP
- Stock Information
- Founded
- MGNX 2000
- CEP 2020
- Country
- MGNX United States
- CEP United States
- Employees
- MGNX N/A
- CEP N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- CEP
- Sector
- MGNX Health Care
- CEP
- Exchange
- MGNX Nasdaq
- CEP NYSE
- Market Cap
- MGNX 151.9M
- CEP 131.6M
- IPO Year
- MGNX 2013
- CEP 2024
- Fundamental
- Price
- MGNX $2.20
- CEP $10.35
- Analyst Decision
- MGNX Hold
- CEP
- Analyst Count
- MGNX 10
- CEP 0
- Target Price
- MGNX $7.17
- CEP N/A
- AVG Volume (30 Days)
- MGNX 551.0K
- CEP 13.1K
- Earning Date
- MGNX 05-08-2025
- CEP 01-01-0001
- Dividend Yield
- MGNX N/A
- CEP N/A
- EPS Growth
- MGNX N/A
- CEP N/A
- EPS
- MGNX N/A
- CEP 0.06
- Revenue
- MGNX $141,329,000.00
- CEP N/A
- Revenue This Year
- MGNX $177.84
- CEP N/A
- Revenue Next Year
- MGNX N/A
- CEP N/A
- P/E Ratio
- MGNX N/A
- CEP $187.24
- Revenue Growth
- MGNX 16.68
- CEP N/A
- 52 Week Low
- MGNX $2.15
- CEP $9.99
- 52 Week High
- MGNX $19.54
- CEP $10.95
- Technical
- Relative Strength Index (RSI)
- MGNX 35.93
- CEP N/A
- Support Level
- MGNX $2.16
- CEP N/A
- Resistance Level
- MGNX $2.49
- CEP N/A
- Average True Range (ATR)
- MGNX 0.17
- CEP 0.00
- MACD
- MGNX -0.00
- CEP 0.00
- Stochastic Oscillator
- MGNX 7.87
- CEP 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.